Comparative evaluation of five aminoglycosides for treatment

Area of Science:

• Pharmacology
• Microbiology
• Infectious Diseases

Background:

• Aminoglycosides are critical antibiotics for treating severe bacterial infections.
• Understanding the in vivo efficacy of different aminoglycosides is crucial for clinical practice.

Purpose of the Study:

• To compare the therapeutic utility of gentamicin, tobramycin, sisomicin, amikacin, and kanamycin.
• To correlate in vitro antibiotic activity with achievable in vivo serum concentrations.

Main Methods:

• Evaluation based on in vitro minimal inhibitory concentration (MIC).
• Correlation with in vivo serum antibiotic concentrations at half the dosing interval.
• Assessment against various bacterial species including E. coli, Enterobacter, Klebsiella, Pseudomonas, Serratia, and Proteus.

Main Results:

• Gentamicin, tobramycin, and sisomicin demonstrate comparable efficacy against E. coli, Enterobacter, and sensitive Klebsiella and Pseudomonas.
• Amikacin shows good efficacy against these bacteria, with higher doses needed for Serratia infections alongside gentamicin and sisomicin.
• Sisomicin excels against Enterobacter and Proteus; tobramycin is superior against Pseudomonas.
• Amikacin is particularly effective against multi-drug resistant Klebsiella, Providencia, and Pseudomonas strains.

Conclusions:

• The study provides a framework for selecting appropriate aminoglycosides based on specific bacterial pathogens and resistance profiles.
• Sisomicin, tobramycin, and amikacin offer distinct advantages in treating infections caused by challenging bacterial species.
• Optimizing aminoglycoside therapy requires considering both in vitro potency and in vivo pharmacokinetics.